On the Barrier Properties of the Cornea: A Microscopy Study of the Penetration of Fluorescently Labeled Nanoparticles, Polymers, and Sodium Fluorescein
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Overcoming the natural defensive barrier functions of the eye remains one of the greatest challenges of ocular drug delivery. Cornea is a chemical and mechanical barrier preventing the passage of any foreign bodies including drugs into the eye, but the factors limiting penetration of permeants and nanoparticulate drug delivery systems through the cornea are still not fully understood. In this study, we investigate these barrier properties of the cornea using thiolated and PEGylated (750 and 5000 Da) nanoparticles, sodium fluorescein, and two linear polymers (dextran and polyethylene glycol). Experiments used intact bovine cornea in addition to bovine cornea de-epithelialized or tissues pretreated with cyclodextrin. It was shown that corneal epithelium is the major barrier for permeation; pretreatment of the cornea with β-cyclodextrin provides higher permeation of low molecular weight compounds, such as sodium fluorescein, but does not enhance penetration of nanoparticles and larger molecules. Studying penetration of thiolated and PEGylated (750 and 5000 Da) nanoparticles into the de-epithelialized ocular tissue revealed that interactions between corneal surface and thiol groups of nanoparticles were more significant determinants of penetration than particle size (for the sizes used here). PEGylation with polyethylene glycol of a higher molecular weight (5000 Da) allows penetration of nanoparticles into the stroma, which proceeds gradually, after an initial 1 h lag phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
Onugwu, A. L., Nwagwu, C. S., Onugwu, O. S., Echezona, A. C., Agbo, C. P., Ihim, S. A., Emeh, P., Nnamani, P. O., Attama, A. A., & Khutoryanskiy, V. V. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.018 · Cited by 350
Self-citationIn situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery
Al Khateb, K., Ozhmukhametova, E. K., Mussin, M. N., Seilkhanov, S. K., Rakhypbekov, T. K., Lau, W. M., & Khutoryanskiy, V. V. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.027 · Cited by 281
Self-citationMansfield, E. D. H., de la Rosa, V. R., Kowalczyk, R. M., Grillo, I., Hoogenboom, R., Sillence, K., Hole, P., Williams, A. C., & Khutoryanskiy, V. V. (2016) · Biomaterials Science · doi:10.1039/c6bm00375c · Cited by 75
Self-citationBongiovì, F., Fiorica, C., Palumbo, F. S., Di Prima, G., Giammona, G., & Pitarresi, G. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00620 · Cited by 44
Alami-Milani, M., Zakeri-Milani, P., Valizadeh, H., Fathi, M., Salatin, S., Salehi, R., & Jelvehgari, M. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1733606 · Cited by 36
Guo, Y., Karimi, F., Fu, Q., G. Qiao, G., & Zhang, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1719995 · Cited by 36
Metadata
- Authors
- Mun, E. A., Morrison, P. W. J., Williams, A. C., & Khutoryanskiy, V. V.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-08-28
- Volume
- 11
- Issue
- 10
- Pages
- 3556-3564
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2057373762
- Cited by
- 145
- References
- 1
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.